» Articles » PMID: 15610106

Serum Prostate-specific Antigen to Predict the Presence of Bladder Outlet Obstruction in Men with Urinary Symptoms

Overview
Journal BJU Int
Specialty Urology
Date 2004 Dec 22
PMID 15610106
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To determine whether prostate specific antigen (PSA) level can usefully predict or exclude bladder outlet obstruction (BOO), in men with lower urinary tract symptoms (LUTS).

Patients And Methods: A cohort of men from 1996 to 1999 who had LUTS caused by BPH was evaluated by serum PSA and pressure-flow urodynamic studies, and a blinded comparison made. The settings were teaching hospitals in London, UK and L'Aquila, Italy. Men (302) were referred by primary-care practitioners with LUTS and a PSA of < 10 ng/mL. Regression analysis was used to predict the extent of BOO, and create likelihood ratios and predictive values for BOO according to the PSA value.

Results: PSA was significantly associated with BOO (P < 0.001; r2 0.07), with significant likelihood ratios altering the probability of BOO. If the PSA was > 4 ng/mL, mild or definite BOO was likely (89%), whereas if the PSA was <2 ng/mL, there was about a one-third chance each of no, mild and definite BOO.

Conclusion: High PSA levels in patients with LUTS are significantly associated with BOO; low PSA levels mean that definite BOO is unlikely.

Citing Articles

Clinical predictors of bladder outlet obstruction in men consulting for routine urological screening.

Raffo M, Capogrosso P, Pozzi E, Belladelli F, Corsini C, Bertini A Int Urol Nephrol. 2025; .

PMID: 40045050 DOI: 10.1007/s11255-025-04432-2.


Development of a clinical decision support tool for Primary care Management of lower Urinary tract Symptoms in men: the PriMUS study.

Edwards A, Agarwal R, Bates J, Bray A, Milosevic S, Thomas-Jones E Health Technol Assess. 2025; 29(1):1-140.

PMID: 39895567 PMC: 11874884. DOI: 10.3310/RGTW5711.


Does bladder outflow obstruction obfuscate the traditional clinical factors that are used to assess the risk of prostate cancer at rapid-access diagnostic clinics?.

Cahill T, Withey S, Hazell S, Cahill D, Kinsella N BJUI Compass. 2025; 6(1):e478.

PMID: 39877561 PMC: 11771501. DOI: 10.1002/bco2.478.


From BPH to male LUTS: a 20-year journey of the EAU guidelines.

Gravas S, Malde S, Cornu J, Gacci M, Gratzke C, Herrmann T Prostate Cancer Prostatic Dis. 2023; 27(1):48-53.

PMID: 37488274 DOI: 10.1038/s41391-023-00700-3.


Development and validation of a clinical nomogram predicting bladder outlet obstruction via routine clinical parameters in men with refractory nonneurogenic lower urinary tract symptoms.

Lee Y, Lee J, Kim J, Lee H, Oh J, Lee S Asian J Androl. 2019; 21(5):486-492.

PMID: 30829291 PMC: 6732887. DOI: 10.4103/aja.aja_127_18.